arasens
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).,ARASENS: A Phase 3 Trial of Darolutamide in Males With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Date. 10 Sep 2017. Session. Poster display ...
| 相關軟體 Cisco Packet Tracer 資訊 | |
|---|---|
 arasens 相關參考資料
ARASENS phase 3 trial of ODM-201 in men with metastatic ...
2014;15:975‒985). Given this promising activity in mCRPC, the ARASENS trial is evaluating ODM-201 plus standard ADT + docetaxel in men ... https://ascopubs.org ARASENS: A phase 3 trial of darolutamide in combination with ...
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). https://ascopubs.org ARASENS: A Phase 3 Trial of Darolutamide in Males With ...
ARASENS: A Phase 3 Trial of Darolutamide in Males With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Date. 10 Sep 2017. Session. Poster display ... https://oncologypro.esmo.org ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of ...
The ARASENS trial will take the next step and evaluate the addition of darolutamide to standard ADT and docetaxel in men with mHSPC. Methods: This is an ... https://www.urotoday.com Darolutamide For Castration-Resistant Prostate Cancer
The primary endpoint of the ARASENS trial is overall survival, and several secondary endpoints include time to CRPC, time to initiation of ... https://www.ncbi.nlm.nih.gov ESMO 2017: ARASENS: A Phase 3 Trial of Darolutamide in ...
ESMO 2017: ARASENS: A Phase 3 Trial of Darolutamide in Males with Metastatic Hormone-Sensitive Prostate Cancer. Madrid, Spain (UroToday.com) Dr. https://www.urotoday.com ODM-201 in Addition to Standard ADT and Docetaxel in ...
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS) ... https://clinicaltrials.gov |